If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
2,015.00    11.00 (0.55%)
Bid:
2,013.00
Ask:
2,014.00
Spread: 1.00 (0.05%)
Market Cap: £80.71b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 May 2023 15:30

RNS Number : 4636Z
GSK PLC
15 May 2023
 

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'), following the approval of the 2020 Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made to deliver in aggregate for 2020 an award level of 575% of base salary, increasing her award level from 550%. It was subject to the same business performance conditions as the main 2020 award, with a three-year performance period from 1 January 2020 to 31 December 2022. The main 2020 award vesting was announced on 14 February 2023. The "top-up" award has now vested on the same basis ie 52% vesting 48% lapsed, following the third anniversary of the grant. The vested shares are subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and details the PSP conditional award that vested, including dividends accrued, on 9 May 2023. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £14.462.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on the "top-up" award granted in 2020 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,729

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-05-09

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFUFLIEDSESI
Date   Source Headline
3rd Jan 20233:00 pmRNSTotal Voting Rights
22nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
21st Dec 20223:35 pmRNSDirector/PDMR Shareholding
21st Dec 20223:30 pmRNSDirector/PDMR Shareholding
15th Dec 20223:30 pmRNSBoard and Committee Changes
13th Dec 20223:30 pmRNSDirector/PDMR Shareholding
7th Dec 20227:00 amRNSStatement: Zantac (ranitidine) litigation
5th Dec 20224:00 pmRNSTransfer of Treasury Shares
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
25th Nov 20224:47 pmRNSPublication of Final Terms of EMTN Notes
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA accepts GSK RSV older adult vaccine for review
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP
27th Oct 20227:05 amRNSGSK announces FDA meeting outcome on daprodustat
27th Oct 20227:00 amRNSContRAst phase III programme for otilimab update
25th Oct 202210:00 amRNSBoard Committee Changes
21st Oct 20227:00 amRNSRSV older adult vaccine submission in Japan
17th Oct 20227:00 amRNSMenveo new single-vial approve by US FDA
17th Oct 20227:00 amRNSMenveo new single-vial approved by US FDA
14th Oct 20222:11 pmRNSDirector/PDMR Shareholding
13th Oct 202212:46 pmRNSDirector/PDMR Shareholding
13th Oct 20229:44 amRNSDirector/PDMR Shareholding
13th Oct 20228:26 amRNSDirector/PDMR Shareholding
13th Oct 20227:00 amRNSEfficacy results for GSK’s older adult RSV vaccine
12th Oct 202211:42 amRNSDirector/PDMR Shareholding
10th Oct 20227:00 amRNSUS FDA approves Boostrix maternal immunisation
7th Oct 20224:38 pmRNSDirector/PDMR Shareholding
7th Oct 20224:24 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:10 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.